CMML diagnostic criteria
| WHO-defined criteria1 . |
|---|
| • Persistent peripheral blood monocytosis ≥1 × 109/L, with monocytes accounting for ≥10% of the white blood cell count |
| • Not meeting WHO criteria for chronic myeloid leukemia, primary myelofibrosis, polycythemia vera, or essential thrombocythemia. The presence of MPN features in the bone marrow and/or mutations in JAK2, CALR, or MPL tend to support MPN with monocytosis rather than CMML |
| • In cases with eosinophilia, no evidence of PDGFRA, PDGFRB, or FGFR1 rearrangement or PCM1-JAK2 |
| • <20% blasts (myeloblasts, monoblasts, and promonocytes) in the bone marrow and peripheral blood |
| • Dysplasia in 1 or more myeloid lineages |
| • If dysplasia is absent or minimal, the diagnosis of CMML may still be made if the other requirements are met and an acquired clonal cytogenetic or molecular genetic abnormality is present in myeloid cells |
| • Or the monocytosis has persisted for at least 3 months and all other causes of monocytosis have been excluded |
| Additional criteria13 |
| • Flow cytometry analysis of peripheral blood monocyte subsets showing that the subset of classical monocytes CD14+,CD16− represents more than 94% of total monocytes |
| WHO-defined criteria1 . |
|---|
| • Persistent peripheral blood monocytosis ≥1 × 109/L, with monocytes accounting for ≥10% of the white blood cell count |
| • Not meeting WHO criteria for chronic myeloid leukemia, primary myelofibrosis, polycythemia vera, or essential thrombocythemia. The presence of MPN features in the bone marrow and/or mutations in JAK2, CALR, or MPL tend to support MPN with monocytosis rather than CMML |
| • In cases with eosinophilia, no evidence of PDGFRA, PDGFRB, or FGFR1 rearrangement or PCM1-JAK2 |
| • <20% blasts (myeloblasts, monoblasts, and promonocytes) in the bone marrow and peripheral blood |
| • Dysplasia in 1 or more myeloid lineages |
| • If dysplasia is absent or minimal, the diagnosis of CMML may still be made if the other requirements are met and an acquired clonal cytogenetic or molecular genetic abnormality is present in myeloid cells |
| • Or the monocytosis has persisted for at least 3 months and all other causes of monocytosis have been excluded |
| Additional criteria13 |
| • Flow cytometry analysis of peripheral blood monocyte subsets showing that the subset of classical monocytes CD14+,CD16− represents more than 94% of total monocytes |